The role involves preparing and executing the launch of Avutometinib and Defactinib for low grade serous ovarian cancer.
Base: $170,000 - $200,000 annually; Bonus/Equity: Incentive plans and start-up equity eligible; Benefits: Health, Dental, Vision, 401k, Tuition Assistance
Must-have
Nice-to-have
Not specified